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Joseph D. Terwilliger2,7,8, Timo Partonen2 & Iiris Hovatta1,2
Acrophobia, an abnormal fear of heights, is a specific phobia characterized as apprehension cued by 
the occurrence or anticipation of elevated spaces. It is considered a complex trait with onset influenced 
by both genetic and environmental factors. Identification of genetic risk variants would provide novel 
insight into the genetic basis of the fear of heights phenotype and contribute to the molecular-level 
understanding of its aetiology. Genetic isolates may facilitate identification of susceptibility alleles 
due to reduced genetic heterogeneity. We took advantage of an internal genetic isolate in Finland in 
which a distinct acrophobia phenotype appears to be segregating in pedigrees originally ascertained 
for schizophrenia. We conducted parametric, nonparametric, joint linkage and linkage disequilibrium 
analyses using a microsatellite marker panel, genotyped in families to search for chromosomal regions 
correlated with acrophobia. Our results implicated a few regions with suggestive evidence for linkage 
on chromosomes 4q28 (LOD = 2.17), 8q24 (LOD = 2.09) and 13q21-q22 (LOD = 2.22). We observed no 
risk haplotypes shared between different families. These results suggest that genetic predisposition 
to acrophobia in this genetic isolate is unlikely to be mediated by a small number of shared high-risk 
alleles, but rather has a complex genetic architecture.
Acrophobia is a pervasive mental disorder, also known as an irrational fear of heights, affecting approximately 
five percent of the world’s population1. It is a disproportional reaction to a common, rational fear, and can be 
characterized as apprehension, triggered by elevated spaces or anticipation of them. Acrophobia is classified as 
a specific phobia under the Diagnostic and Statistical Manual of Mental Disorders (DSM-V), and its aetiology 
is influenced by both genetic and environmental factors2,3. While demonstrating high comorbidity rates with 
various psychiatric disorders and diseases, such as different anxiety disorders or major depression4,5, acquisition 
of acrophobia is believed to differ from other phobias. It may be mediated through a non-associative pathway6, 
rather than conditioning or learning from negative or traumatic experiences7.
The symptoms of individuals suffering from acrophobia involve changes in behavioural, cognitive and physi-
ological functioning, such as confusion and dizziness, when exposed to heights7. Physiologically associated with 
anomalies in balance control and avoidance behaviour, acrophobia is a consequence of an underlying biological 
anomaly involving impaired visual detection of body sway8. In healthy subjects, posture control is obtained by 
integrated processing of vestibular, visual and proprioceptive inputs9. However, in people suffering from acro-
phobia, dysfunction in one of the feedback mechanisms may lead to increased dependence on other stimuli. 
In particular, the presence of vestibular dysfunction causes increased dependence on visual or proprioceptive 
information to keep balance and constant anticipation of matching the natural oscillation of body sway with 
visual flow stimulation7. This matching is the root cause of the feeling of lack of stability, especially when exposed 
to high places10.
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Although the biological mechanisms of acrophobia have been thoroughly investigated8, little is known about 
its molecular basis. As in the case of other complex psychiatric diseases, efforts to localize genetic variants pre-
disposing to acrophobia are hindered by the complexity of the clinical phenotype and the heterogeneity of the 
studied samples11. Therefore, isolated populations offer several advantages in studying the genetic architecture 
of such complex human diseases, both when rare12,13 or common14 variants are thought to be involved in the 
genetic aetiology of the condition. Firstly, the enrichment of the risk alleles in an isolated population might help 
enable their identification. Furthermore, the shared environmental and cultural homogeneity is highly beneficial 
as potent exposures to environmental risks during the lifetime, possibly influencing the aetiology of the disorder, 
are not routinely evaluated and might therefore be difficult to detect11.
To reduce genetic heterogeneity we have used an isolated homogenous population from north-eastern Finland 
with small number of founders. This population, described elsewhere15,16, has been intensively characterized 
using multiple high-quality historical and health-care registries and was previously studied due to increased life-
time risk of schizophrenia, compared with the rest of Finland17. While the collection of the schizophrenia sample 
was ongoing, we observed that a large number of family members had distinct and severe acrophobia that segre-
gated independently from schizophrenia. In this study, we aimed to map genetic loci predisposing to this specific 
phenotype. We hypothesized that predisposition to acrophobia may be mediated by a small number of high risk 
susceptibility variants segregating in this isolate, and that we could possibly identify them through a genome-wide 
linkage scan using microsatellite markers, which had been genotyped as a part of earlier linkage-based gene 
mapping studies17,18.
Results
Our sample was composed mostly of large multigenerational pedigrees with multiple individuals affected with 
acrophobia and at least one parent born in the isolate (Fig. 1). It included 642 people, 42 of them affected only with 
acrophobia (6.5%) and 75 with acrophobia comorbid with schizophrenia (11.7%; Table 1). As part of earlier stud-
ies17,18, we had genotype information available from 367 individuals, assessed by a genome-wide microsatellite 








individuals 29 (50.9%) 46 (80.7%)
Individuals
Male 306 (47.7%) 306 (47.7%)
Female 336 (52.3%) 336 (52.3%)
Affected individuals
Male 15 (4.5%) 31 (9.2%)
Female 27 (8.8%) 44 (14.4%)
Genotyped individuals
Affected 42 (100%) 75 (100%)
Unaffected 325 (54.2%) 292 (51.5%)
Average pedigree size 11.26 (3 to 54 individuals) 11.26 (3 to 54 individuals)
Table 1.  Data structure and summary statistics of the analysed pedigrees. Pedigree characteristics computed 
with PedStats60. aStudy conducted on individuals with pure acrophobia, where all individuals with comorbid 
schizophrenia were excluded from the analysis. bStudy conducted on individuals with acrophobia (N = 75), 
including individuals with comorbid schizophrenia (N = 33).
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marker panel. As parametric and nonparametric (model-free) methods have different strengths and weaknesses 
in detecting linkage19, we applied both techniques across the genome. Two-point parametric analysis has been 
proven to be more powerful than nonparametric analysis, provided that the trait and marker locus are specified 
correctly. However, in case the parametric model is incorrect, the power of the parametric linkage might be 
exceeded by nonparametric methods. As the inheritance pattern in our study is unknown, we decided to conduct 
analyses with both methods. In the parametric analysis, we used dominant and recessive models due to unknown 
inheritance pattern, followed by nonparametric analysis, and joint linkage and linkage disequilibrium analysis 
(Fig. 2). While two-point analysis examines linkage of a disease to a single marker locus at a time, multipoint 
analysis evaluates linkage to multiple markers simultaneously. This results in a greater power to detect linkage, but 
also an inflation of type I error (false positive) if marker-related information is incorrect20. We performed multi-
point, but not two-point nonparametric analysis, because of the limitations in the size of the pedigrees, which can 
be analysed, without being divided, by currently available software21. Due to the significant number of individuals 
with acrophobia comorbid with schizophrenia, we analysed all individuals with acrophobia, but also conducted 
separate analyses with individuals with pure acrophobia and pure schizophrenia to investigate whether any signal 
was mainly coming from genetic factors influencing susceptibility to schizophrenia independent of acrophobia.
Parametric two-point recessive and dominant linkage analysis. We first carried out parametric 
two-point linkage analysis to identify genetic regions linked with acrophobia. The strongest evidence for linkage 
in the acrophobia sample (including cases with comorbid schizophrenia) was obtained with marker D5S2115 
(LOD = 2.16) using a dominant model. In the pure acrophobia sample, the same marker yielded a LOD score 
of 0.58 (dominant model), suggesting that this finding may be mainly driven by the schizophrenia phenotype. 
This was further confirmed by analysing all individuals with schizophrenia without comorbid acrophobia 
(LOD = 1.57, dominant model). For the pure acrophobia sample, we obtained the highest LOD score with marker 
D8S373 (LOD = 2.09) adopting a recessive inheritance model. Since in the acrophobia with comorbid schizo-
phrenia sample the same marker yielded a LOD score of 0.51 (recessive model) and in the pure schizophrenia 
sample a LOD score of 0.00 (recessive model), this signal may be produced mainly by the acrophobia phenotype. 
Table 2 shows the results of the two-point analyses for markers giving the strongest evidence of linkage (LOD 
score of >1.6).















D5S2115 5 147.47 0.58 0.39 2.16 1.54
D13S173 13 87.49 1.21 0.99 1.44 1.89
D1S1728 1 97.17 1.04 1.20 0.52 1.62
D8S373 8 163.74 0.32 2.09 0.02 0.51
D21S1441 21 7.8 0.25 1.61 0.00 0.47
Table 2.  LOD scores from the two-point parametric analysis (FASTLINK) using dominant and recessive 
models. All markers with LOD score above 1.6 (in bold), in any of the models, are included in the Table.
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Parametric multipoint linkage analysis. We carried out parametric multipoint analysis for chromo-
somes with markers and models which yielded LOD score of >2.0 in at least one parametric two-point analysis 
(chromosome 5: dominant model in acrophobia with comorbid schizophrenia; and chromosome 8: recessive 
model in pure acrophobia). In the acrophobia sample (including cases with comorbid schizophrenia), marker 
D5S2115 yielded a maximum LOD score of 0.054 (α = 0.15, dominant model). In the pure acrophobia sample the 
highest LOD score on chromosome 8 was with marker D8S373 (0.533, α = 1.00, recessive model).
Nonparametric multipoint linkage analysis. We next carried out multipoint nonparametric 
genome-wide linkage analysis with empirical NPL_ALL model (Fig. 3), measuring if a few founder-alleles are 
overly represented in affected individuals. Among the acrophobia sample (including cases with comorbid schiz-
ophrenia), the maximum LOD score of 2.91 was detected with marker D13S173, while for the pure acrophobia 
sample the same marker reached LOD score of 2.11. In the pure acrophobia sample the most significant evidence 
of linkage (LOD score = 2.22) was observed with marker D13S162. Markers D13S173 and D13S162 are located 
37.8 cM apart and are therefore not strongly linked.
Figure 4 shows the results from the multipoint nonparametric linkage analysis with empirical NPL_PAIR 
model measuring the sum of conditional kinship coefficients for all affected pairs. For acrophobia sample (includ-
ing cases with comorbid schizophrenia), NPL_PAIR approach yielded the maximum LOD score with marker 
D1S2817 (LOD = 2.52), while in the pure acrophobia sample the LOD score for the same marker was 0.47. The 
strongest finding for NPL_PAIR analysis in the pure acrophobia sample was a LOD score of 2.17 with marker 
D4S2394.
Joint linkage and linkage disequilibrium analysis. We hypothesized that reduced genetic heterogeneity 
in the genetic isolate would lead to the majority of the cases carrying the same predisposing variant, detectable as 
linkage disequilibrium (LD). Therefore, we performed PSEUDOMARKER analysis of LD conditional on linkage 
(Fig. 5). The strongest evidence for association to acrophobia (including cases with comorbid schizophrenia) 
was detected for markers D4S2431 (P = 0.0003, recessive model) and D14S267 (P = 0.0019, dominant model). 
In the pure acrophobia sample the same markers yielded P values of 0.1704 and 0.0244, respectively. For the pure 
acrophobia sample the strongest association was obtained to markers D17S2196 (P = 0.0054, dominant model) 
and D1S235 (P = 0.0054, recessive model). These results are consistent with the lack of evidence of linkage in the 
sample.
Power simulation. To test the statistical power of the analysed sample, we performed simulation with 
SLINK22 software. We obtained average maximum LOD scores of 5.77 and 5.03 with the dominant and recessive 
model, respectively. Furthermore, 31% of replicates under the dominant and 12% of replicates under the recessive 
model reached the conventional LOD score threshold of 3.0. Therefore, this sample has adequate statistical power 
to obtain significant evidence for linkage to major loci predisposing to acrophobia.
Discussion
We aimed to find genetic loci predisposing to acrophobia in a genetically isolated population with the hypothesis 
that due to reduced genetic heterogeneity, a few risk alleles predisposing to the phenotype might be identified. 
While several loci attained LOD score of >2.0, we observed no genome-wide significant evidence for linkage at 
any of the studied markers.
Figure 3. Results from multipoint nonparametric analysis with NPL_ALL model (SimWalk2). The upper 
panel shows comorbid acrophobia and schizophrenia sample, while the lower panel shows pure acrophobia 
sample.
www.nature.com/scientificreports/
5Scientific RepoRts | 6:39345 | DOI: 10.1038/srep39345
We detected the strongest evidence of linkage to acrophobia on chromosomal region 13q21-q22 with a peak 
on marker D13S162 (LOD = 2.22; pure acrophobia sample). To our knowledge, this region has not been previ-
ously associated with phobias or other anxiety disorders. SNP rs2323266, located 14.01 Mb from marker D13S162 
and close to the protocadherin 20 (PCDH20) gene in this region, has been previously connected to positive 
symptom dimension in a genome-wide association study (GWAS) of schizophrenia (P = 3 × 10−6)23. However, 
markers D13S162 and rs2323266 are not located within the same LD block. Thus, in our sample, the finding in 
this chromosomal region seemed to be specific for acrophobia.
We obtained the second strongest evidence of linkage for acrophobia on chromosomal region 4q28 for marker 
D4S2394 (LOD = 2.17; pure acrophobia sample). Again, in our study, this signal appeared to be mainly coming 
from acrophobia and not schizophrenia phenotype (LOD = 0.52; pure schizophrenia sample). This region has not 
been previously associated with anxiety disorders or schizophrenia.
Chromosomal region 8q24.2-q24.3 with marker D8S373 (LOD = 2.09) was the third region most strongly 
linked to acrophobia. It has previously been associated with bipolar disorder24–26 and schizophrenia27. However, 
in our samples of acrophobia with comorbid schizophrenia (LOD = 0.51) and pure schizophrenia (LOD = 0.00) 
this region did not provide evidence for linkage. This region encompasses 49 genes, including several candidate 
genes for psychiatric disorders: potassium voltage-gated channel subfamily KQT member 3 (KCNQ3)24,28 coding 
for a voltage-gated potassium channel; adenylate cyclase 8 (ADCY8)24 involved in fear learning and memory, and 
long-term memory consolidation29; Ly6/Neurotoxin 1 (LYNX1)30 (located on 8q24.3 near D8S373) involved in the 
development of visual perception including binocular vision and motor learning during the critical period31–34; 
and activity-regulated cytoskeleton-associated protein (ARC)29 connected to long-term potentiation and the con-
solidation of long-term memory. Our strongest evidence for LD conditional on linkage (P = 0.0054, dominant 
model) was observed with markers located in chromosomal region 17p11. The region harbours hundreds of 
Figure 4. Results from multipoint nonparametric analysis with NPL_PAIR model (SimWalk2). The upper 
panel shows comorbid acrophobia and schizophrenia sample, while the lower panel shows pure acrophobia 
sample.
Figure 5. Results from linkage disequilibrium conditional on linkage analysis (PSEUDOMARKER). 
Recessive analysis is shown with triangles and dominant analysis with dots. The upper panel shows comorbid 
acrophobia and schizophrenia sample, while the lower panel shows pure acrophobia sample.
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genes, however, to our knowledge, none of them have been previously directly connected to phobias or other 
anxiety disorders.
Several of the chromosomal regions we identified seemed mainly specific for schizophrenia. The most signifi-
cant of those regions were 5q31 and 1q32, discussed above for markers D5S2115 and D1S2817. Both of them have 
been previously associated with schizophrenia in numerous studies35–38.
Furthermore, several markers on the long arm of chromosome 13, localized between 13q31 and 13q33, 
showed evidence of linkage (LOD > 2.0) to both pure acrophobia and acrophobia with comorbid schizophrenia, 
and also weak linkage to pure schizophrenia (maximum LOD = 1.26). Therefore, this region may harbour vari-
ants influencing susceptibility to both phenotypes. As specific phobia subtypes have high comorbidity with other 
anxiety disorders4 and psychiatric disorders, such as schizophrenia39, the same genetic variants affecting brain 
function may be involved in both diseases partially explaining the high comorbidity rates and overlapping biolog-
ical symptoms. Intriguingly, several shared symptoms related to balance control and avoidance behaviour, central 
in acrophobia, have been described in schizophrenia and depressive disorders. Most importantly, irregularities in 
eye movement and head coordination propensities associated with difficulties in classification of relevant visual 
stimuli have been observed in schizophrenia patients40. Furthermore, the primary vestibular disfunction leading 
to chronic dizziness occurs both in specific phobias and depressive disorders41. Lastly, acrophobia is a signifi-
cant predictor of later depressive episodes, generalized anxiety and panic attacks42. Together, these observations 
may be related to partially shared genetic predisposition to acrophobia and other comorbid psychiatric diseases, 
including schizophrenia.
We recognise the hypothesis-generating character of our study. It included a large number of genotyped mark-
ers (570) and analysed models (6). Although this serves to strengthen the study, it inevitably lead to multiple 
statistical testing. However, as the tests carried out are not completely independent, the adjustment for multiple 
testing is not straightforward43. Consequently, avoidance of the type I error might unintentionally inflate the type 
II error (false negative). Therefore, we decided to provide the LOD scores and their corresponding uncorrected 
nominal P values, when applicable, and rely on the future studies of acrophobia in independent samples to assess 
whether the chromosomal regions identified in this study harbor true predisposing variants.
In recent years, single nucleotide polymorphisms (SNPs) have replaced microsatellite markers due to their 
lower genotyping costs. This technical advance has enabled genome-wide association studies (GWASs) in which 
thousands of individuals are genotyped. Consequently, the usage of microsatellite markers, a class of short tan-
dem repeats (STRs), has severely decreased. However, due to their highly polymorphic nature microsatellites 
are still considered more informative than the diallelic SNPs44 in studying the genetic architecture of complex 
human diseases. Unlike in the population-based association studies, the enrichment of the risk alleles in isolated 
populations and higher degree of LD may enable the identification of genetic risk factors in a smaller sample and 
with smaller number of markers, as shown previously for neuropsychiatric diseases, such as schizophrenia and 
autism11,17,45.
In conclusion, our findings suggest that the genetic basis of acrophobia is highly complex, even in this genetic 
isolate, as we were not able to identify high-risk variants shared by several families. However, we identified several 
chromosomal regions with suggestive evidence for linkage which could be investigated further in other acropho-
bia samples and meta-analyses of such datasets having an increased statistical power.
Methods
Study sample. The sample was composed mostly of large multigenerational pedigrees with multiple affected 
individuals and at least one parent born in the isolate (Fig. 1). It comprised 57 families including 642 people, 75 of 
them affected with acrophobia and schizophrenia (11.7%) and 42 with pure acrophobia (6.5%). All pedigrees are 
part of a Finnish severe mental disorders family collection of the National Institute for Health and Welfare17,18,46,47. 
We traced ancestors from Finnish Population Registries and performed a genealogical study in accordance with 
published criteria47.
Data from psychiatric case notes and treatment facilities concerning affected individuals and blood samples 
were collected between 1991 and 200248. Structured Clinical Interviews for DSM-IV (SCID-I)49 followed by a 
diagnostic assessment performed in accordance with the Diagnostic and Statistical Manual of Mental Disorders, 
4th edition (DSM-IV) criteria50 and Operational Criteria Checklist (OPCRIT)44 were conducted at a later time, 
between 1998 and 200248. Following the interviews, assessment was undertaken independently by two psychia-
trists (T.Par. and R.A.). In case of disagreement, third psychiatrist (J.L.), reanalysed the case in order to gain con-
sensus17. The sample used in the study is detailed in Table 1. The ethical review board of the National Institute for 
Health and Welfare (THL), formerly the National Public Health Institute of Finland (KTL), approved all experi-
mental protocols in this study and the methods used were carried out in accordance with the approved guidelines. 
Informed consent was obtained from all participants before enrolment in the study.
Genotyping. We analysed 575 autosomal microsatellite markers across the genome that had been geno-
typed as a part of earlier linkage-based gene mapping studies17,48. We had genotype information available from all 
affected and 292 unaffected individuals.
Statistical analyses. We performed statistical analyses separately for acrophobia with comorbid schizo-
phrenia and pure acrophobia sample to discriminate between the possible shared and separate genetic signals 
associated with the phenotypes. We further followed with statistical analysis of the pure schizophrenia sample for 
the most interesting results. We first checked all genotypes for Mendelian inconsistencies with PedCheck soft-
ware51 and removed erroneous genotypes, which accounted for less than 0.08% of all genotypes. We performed all 
analyses as affected-only, meaning that all phenotypes of healthy individuals and those with unknown affection 
status were treated as unknown, due to the fact that unaffected family members were not systematically assessed52.
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Parametric two-point recessive and dominant linkage analysis. We performed two-point paramet-
ric linkage analysis with statistical software package FASTLINK 4.1 P under a recessive and dominant mode of 
inheritance with, respectively, penetrance of 0.001% and 90%, disease allele frequency of 0.00001 and 0.01, and 
phenocopy rates of 0 and 0.01. FASTLINK 4.1 P program was implemented in a helper program AUTOGSCAN53.
Parametric and nonparametric multipoint linkage analysis. We carried out multipoint paramet-
ric and nonparametric linkage analysis with SimWalk2 version 2.9654–56. For the nonparametric analysis, two 
statistics were examined: empirical NPL_ALL model, measuring if few founder-alleles are overly represented in 
affected individuals, and NPL_PAIR, measuring the sum of conditional kinship coefficients for all affected pairs. 
In all analyses, pedigrees with just one, non-related affected, were not analysed by the program, limiting the total 
number of pedigrees evaluated to five for pure acrophobia and 15 for acrophobia with comorbid schizophrenia 
sample. Files for SimWalk2 software were prepared with free data conversion program Mega257.
Stage III: Joint linkage and linkage disequilibrium (LD) analysis. We performed the linkage disequi-
librium conditional on linkage analysis with PSEUDOMARKER software package under default dominant and 
recessive models58,59. PSEUDOMARKER program uses a likelihood-based method, which combines pedigrees of 
heterogeneous relationship structures, singletons and others, into one unified analysis.
Power simulation. The power of the analysed pedigrees to detect linkage was estimated with SLINK simu-
lation program and the replicates were analysed with ISIM analysis program implemented in SLINK package23. 
The analysis was performed under PSEUDOMARKER recessive and dominant models with the assumption of 
complete linkage (θ = 0.0) between marker and trait locus, and with penetrance and disease allele frequency iden-
tical to those used in the linkage analysis. We assumed the disease prevalence of five percent1 for acrophobia. The 
analysis was performed using 100 replications.
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